Is ICUI a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The Infusion Systems replacement cycle, with revenue (fy2025) at ~$2.23 billion. The bear case rests on regulatory and quality exposure is the most specific risk. Analysts covering it are spread from $165.00 to $200.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Regulatory and quality exposure is the most specific risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $165.00, -11.2% from the $185.78 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The Infusion Systems replacement cycle. Infusion Systems grew about 12% organically in the second quarter of 2026, driven largely by competitive win installations rather than upgrades within the existing base. The most optimistic analyst target on ICUI is $200.00, +7.7% from the $185.78 price. That figure is only reachable if this thesis works close to its best case.

Regulatory and quality exposure is the most specific risk. The FDA issued a warning letter in April 2025 stating that ICU Medical made changes to the Medfusion Model 4000 syringe pump and the CADD Solis VIP ambulatory pump without the required premarket submissions, and that letter followed a run of recalls dating back to the Smiths integration, so remediation costs and any further enforcement action remain open items. Several plaintiff law firms announced securities fraud investigations after that disclosure, and while ICU Medical describes its litigation as ordinary course, headline risk on this front has not gone away. Operationally, tariffs are running at an estimated $30 million to $40 million annually, yen weakness has been a multi-year currency headwind, and hospital capital budgets can defer pump purchases in a downturn. Financially, leverage near 2.3 times leaves less room for a stumble than a debt-free peer would have, and the gap between guided GAAP EPS of roughly $2.89 to $3.29 and adjusted EPS of roughly $8.60 to $9.00 is large enough that how an investor treats amortization and restructuring charges materially changes what the stock looks like. The most pessimistic published target is $165.00, -11.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

ICU Medical makes hospital infusion consumables, pumps and critical care products, and is still digesting its Smiths Medical acquisition.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Infusion Systems replacement cycle) stalling in the reported numbers rather than in the narrative, the risk above (regulatory and quality exposure is the most specific risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It sells the consumables and hardware used to deliver fluids and drugs to hospital patients: IV sets and needle-free connectors (the CLAVE family), oncology and vascular access products, tracheostomy devices, large volume and syringe and ambulatory infusion pumps such as the Plum Duo, Plum Solo, CADD and Medfusion lines, plus critical care items like temperature management and cardiac monitoring. Its customers are hospitals, alternate-site care providers and distributors, largely through group purchasing organization contracts.

Consumables, Infusion Systems and Vital Care. In full year 2025 Consumables generated about $1.11 billion, Infusion Systems about $684 million and Vital Care about $438 million, for total revenue of roughly $2.23 billion. Consumables is the recurring, higher-margin base; Infusion Systems is the capital hardware plus software layer that pulls consumables along with it; Vital Care is the most mixed and the segment management has been reshaping.

ICU Medical closed the roughly $2.35 billion cash-and-stock purchase of Smiths Medical from Smiths Group in January 2022, adding syringe and ambulatory infusion pumps, vascular access and vital care products and roughly doubling company size. It also added substantial debt, a large integration and quality remediation workload, and manufacturing complexity that took years longer to work through than planned. Most of the margin recovery, facility consolidation and IT integration described in recent quarters traces directly back to that deal.